LifeMD, Inc. (LFMD)
| Market Cap | 218.28M |
| Revenue (ttm) | 194.06M |
| Net Income (ttm) | 11.25M |
| Shares Out | 47.97M |
| EPS (ttm) | 0.25 |
| PE Ratio | 18.26 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 635,290 |
| Open | 4.520 |
| Previous Close | 4.570 |
| Day's Range | 4.440 - 4.590 |
| 52-Week Range | 2.560 - 15.840 |
| Beta | 1.77 |
| Analysts | Strong Buy |
| Price Target | 9.14 (+100.88%) |
| Earnings Date | May 6, 2026 |
About LFMD
LifeMD, Inc. operates as a direct-to-patient telehealth company, engages in the provision of patients access to virtual medical care and pharmacy services in the United States. It offers telehealth platform comprising Rex MD, a men’s telehealth platform that provides virtual diagnosis, treatment, and prescription medications for men’s health conditions, including erectile dysfunction, premature ejaculation, hair loss, insomnia, weight loss, and performance anxiety; and ShapiroMD that provides virtual medical treatment, prescription medications,... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for LFMD stock is "Strong Buy." The 12-month stock price target is $9.14, which is an increase of 100.88% from the latest price.
News
LifeMD to Report First Quarter 2026 Financial Results on May 6
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three months ende...
LifeMD® Now Offering Eli Lilly and Company's Foundayo™ (orforglipron), a New GLP-1 Pill for Weight Management
LifeMD expands its weight management program with the addition of Foundayo, offering eligible patients an oral alternative to injectable GLP-1 therapies through LillyDirect® LifeMD expands its weight ...
LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program
Delivering up to $1,200 in annual patient savings on branded GLP-1 therapy, expanding LifeMD's collaboration with Novo Nordisk Delivering up to $1,200 in annual patient savings on branded GLP-1 therap...
LifeMD Declares Quarterly Dividend on Series A Cumulative Perpetual Preferred Stock
NEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that its Board of Directors has authorized a cash dividen...
LifeMD Appoints Veteran Healthcare Finance Executive as Chief Financial Officer and Expands Leadership Team
NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Atul Kavthekar as Chief Financial Offi...
LifeMD Earnings Call Transcript: Q4 2025
Delivered record Q4 and full-year results with 25% revenue growth, strong subscriber gains, and margin expansion. Aggressive investments in patient acquisition and AI-driven care are expected to drive 2026 revenue to $220–$230 million, with pharmacy and specialty care as key growth drivers.
LifeMD Reports Fourth Quarter and Full Year 2025 Results
Full year 2025 revenue grew 25% to $194.1 million; adjusted EBITDA rose 309% to $15.3 million. Fourth quarter revenue increased 4% to $46.9 million; adjusted EBITDA rose 348% to $4.8 million.
LifeMD to Participate in Two Investor Conferences During March
NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced that management will be participating in the following in...
LifeMD to Report Fourth Quarter 2025 Financial Results on March 9
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and 12 month...
LifeMD Announces Closing of $50 Million Revolving Credit Facility with Citizens Bank, N.A.
NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care and pharmacy services, today announced the closing of a new senior secured revolving...
LifeMD Expands Collaboration with Novo Nordisk as Recognized Telehealth Partner Offering Newly Approved Wegovy® Pill
Adds first and only FDA‑approved oral GLP‑1 to its virtual weight management offering, expanding access to affordable, branded treatment options Adds first and only FDA‑approved oral GLP‑1 to its virt...
LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME's America's Growth Leaders of 2026
NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy solutions, today announced it has been recognized on both the ...
LifeMD Stock Plummets After Q3 Earnings: Here's Why
LifeMD Inc. (NASDAQ: LFMD) shares fell after the company released its third-quarter earnings report after Monday's closing bell, missing analyst estimates on the top and bottom lines.
LifeMD Earnings Call Transcript: Q3 2025
Q3 2025 saw 13% revenue growth and 30% higher adjusted EBITDA, with strong telehealth and RexMD performance. Insurance enablement and new oral GLP-1 therapies are set to drive growth in 2026, while the company maintains a robust balance sheet and focuses on core virtual care.
LifeMD Reports Third Quarter 2025 Results
Total revenue increased 13% year-over-year to $60.2 million, and adjusted EBITDA rose 20% to $5.1 million. Telehealth revenue grew 18% to $47.3 million, while telehealth adjusted EBITDA increased 30% ...
LifeMD® to Offer Market-Leading Pricing for GLP-1 Medications Wegovy® and Ozempic® in Continued Collaboration with Novo Nordisk
LifeMD expands access to Wegovy and Ozempic at the lowest cash-pay pricing, reinforcing its commitment to patient affordability and high-quality care LifeMD expands access to Wegovy and Ozempic at the...
LifeMD to Participate in the BTIG Digital Health Forum
NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services and pharmacy, today announced its participation in the virtual BTIG Digital...
LifeMD Reschedules Third Quarter 2025 Earnings Release and Conference Call to November 17
NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual healthcare services and pharmacy, today announced that the Company has rescheduled its third quar...
LifeMD Divests Majority Interest in WorkSimpli Software, Positioning Company as a Pure-Play Virtual Care and Pharmacy Platform
Transaction Values WorkSimpli at $65 Million Enterprise Value; Supports LifeMD's Strategic Focus on Scaling its Virtual Care and Pharmacy Businesses Transaction Values WorkSimpli at $65 Million Enterp...
LifeMD (LFMD) Faces Lawsuit Over Alleged Concealment of Cost and Refund Woes in Key Segments, According to Hagens Berman
LFMD Investors with Losses Encouraged to Contact Hagens Berman Before Oct. 27th Deadline SAN FRANCISCO , Oct. 24, 2025 /PRNewswire/ -- A new federal securities fraud class action lawsuit has been file...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LifeMD
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding In LifeMD To Contact Him Directly To Discuss Their Options If you purchased or...
LifeMD to Report Third Quarter 2025 Financial Results on November 6
NEW YORK, Oct. 23, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, announces that it will report financial results for the three and nine mon...
LifeMD Names Dr. Tara Scott as Ambassador and Clinical Advisor for its Women's Health Program
NEW YORK, Oct. 22, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the appointment of Tara Scott, MD, widely known as “ The H...
LifeMD (LFMD) Sued for Allegedly Misleading Investors on Growth Guidance, According to Hagens Berman
Investors who lost money in LifeMD after its stock plunged 44 percent due to allegedly misleading financial statements are urged to contact Hagens Berman.
LFMD INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of LifeMD
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In LifeMD To Contact Him Directly To Discuss Their Options